A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumors

Summary

A Phase I/IIa Study of the Safety and Tolerability of T3011 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors

Timeline

Start

2020-04-21

Primary completion

2023-07

Completion

2024-01

Publications

• Ji D, Fu W, Liu Y, Shen W, Kuang M, Ning Z, Sang Y, Chen G, Zhang J, Zhou Z, Xu D, Jin X, Wu J, Zhou X, Zhao J, Wang L, Liu Y, Zhang X, Yan R, Chen X, Zhou G, Niu J, Hu X. First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC. BMC Med. 2026 Feb 20;24(1):177. doi: 10.1186/s12916-026-04695-1.

Drugs

Indications